Foundation Medicine Seeks "Go-To" Companion Diagnostic Status For Sequencing Test
This article was originally published in The Pink Sheet Daily
Foundation says its test service will transition next-generation sequencing from the research bench to routine clinical practice, with the ultimate goal of supplanting the need for individual gene mutation tests to drive oncology drug therapy decisions.
You may also be interested in...
Biogen will purchase GSK spinout Convergence to bolster its pain portfolio, while Tekmira and OnCore are merging to create a new company focused on hepatitis B. Two J&J units struck deals during the week in Alzheimer’s and gastrointestinal indications, as Lilly teamed up with Merck and Bristol for combo trials to keep its drugs relevant in the PD-1 world.
Foundation Medicine gets a $400 million cash infusion to continue its cancer diagnostic R&D while Roche acquires a majority interest in the company and will use its products to guide and optimize its clinical trials for cancer immunotherapies.
The Domain Associates/Rusnano tie-up looks new on the surface, but is driven by a familiar imperative – the need to find new funding streams for biotechs still working to build up their exit value.